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D efinitive concurrent chemoradiotherapy (CCRT) is one of the standard treatments for unresect-
able stage III lung cancer.  When administered concur-
rently with a cisplatin/docetaxel regimen,  it shows a 
trend toward improved median progression-free time 
and 2-year overall survival (OS) compared with second- 
generation chemotherapy [1].  Patients receiving cispla-
tin/docetaxel also tend to show a lower rate of distant 
metastases at the first recurrence site in comparison 
with those who receive second-generation chemother-
apy.  Recent studies have shown that the administration 
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The aim of this study was to investigate whether volumetric positron emission tomography (PET) parameters 
are prognostic predictors in stage III non-small cell lung cancer patients receiving definitive concurrent chemo-
radiotherapy (CCRT) with cisplatin/docetaxel.  Cases involving definitive CCRT were reviewed retrospectively,  
and the maximum standardized uptake value,  metabolic tumor volume (MTV) and total lesion glycolysis (TLG) 
were calculated.  The relationships between these PET parameters and prognosis were analyzed.  MTV and TLG 
were significant predictors of distant metastasis-free survival (DMFS) (p= 0.0003 and 0.0005,  respectively) and 
progression-free survival (PFS) (p= 0.001 and 0.0007,  respectively).  The three-year DMFS rates in patients with 
low and high MTV were 13.3% and 64.6%,  respectively,  and the corresponding values in those with low and 
high TLG were 13.3% and 65.2%,  respectively.  The three-year PFS rates in patients with low and high MTV 
were 13.3% and 57.8%,  respectively,  and the corresponding values in patients with low and high TLG were 
13.3% and 57.8%,  respectively.  However,  MTV and TLG were not predictors of local control or overall sur-
vival.  We demonstrated that volumetric PET parameters were predictors of patients receiving definitive CCRT.  
Our findings contradict the findings of previous reports and warrant further research to validate them.
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of durvalumab after CCRT improves progression-free 
survival (PFS) and OS.  The incidence of new metastatic 
lesions was 33.8% in the CCRT-alone group and 22.5% 
in the durvalumab group,  which was probably attribut-
able to the improvement in PFS as a result of the sup-
pression of distant metastases.  Since the appearance of 
distant metastases suggests that curing the disease has 
generally become more difficult,  biomarkers for pre-
dicting distant metastases are desired.
18F-Fluorodeoxyglucose (18F-FDG) positron emis-
sion tomography/computed tomography (PET/CT) is 
useful for the staging and prognosis of malignant 
tumors.  Although the maximum standard uptake value 
(SUVmax) has been adopted as a PET parameter [2],  
volumetric evaluations can facilitate assessments of 
overall tumor activity in addition to single-voxel assess-
ments such as SUVmax [3 , 4].  Volumetric PET param-
eters for lung cancer have been reported to be useful in 
assessing responses to CCRT [5 , 6] and chemotherapy 
[7].  Although some studies have examined the correla-
tion between volumetric PET parameters and OS or PFS 
in patients receiving chemoradiotherapy,  only a few 
studies have examined the distant metastasis-free sur-
vival rate (DMFS).  Moreover,  even fewer reports have 
included cases in which a cisplatin/docetaxel regimen 
was concurrently used [8].
Thus,  the purpose of this study is to investigate 
whether volumetric PET parameters can serve as pre-
dictors of DMFS for non-small cell lung cancer 
(NSCLC) patients who received CCRT with cisplatin/
docetaxel.
Materials and Methods
Patients. The study was approved by the institu-
tional ethics committee (No. 1809-018).  Patients who 
received CCRT between April 2006 and December 2017 
at the authors’ hospital were reviewed retrospectively.  
Staging was performed according to the 7th edition of 
the TNM Classification of Malignant Tumors.  Lymph 
nodes with a short diameter of 1 cm or more were 
defined as metastases.  Lymph nodes of less than 1 cm 
were defined as metastases if accumulations were 
observed on PET/CT as judged by a board-certified 
radiologist.  If a biopsy or resection was required in 
addition to imaging,  at the discretion of the respiratory 
physicians,  lymph node metastasis was diagnosed 
pathologically.  The eligibility criteria were as follows:  
staging with a specified PET/CT device,  stage III 
NSCLC,  definitive radiotherapy,  concurrent use of 
chemotherapy with cisplatin/docetaxel [1],  and no 
administration of neoadjuvant therapy before the start 
of CCRT.  After treatment,  follow-up CT and magnetic 
resonance imaging were performed periodically,  with 
intervals determined by the individual respiratory phy-
sician.  All procedures were in compliance with the 
ethical standards of the 1964 Declaration of Helsinki 
and subsequent modifications.  Written informed con-
sent was obtained before CCRT.  In accordance with the 
rules of the ethics committee,  opportunities to opt out 
of the study were provided before this research was 
started.
Treatment. Indications for definitive CCRT for 
all cases were discussed at the respiratory conference 
and finally determined by a board-certified chest medi-
cal oncologist and a radiation oncologist.  All patients 
received three-dimensional conformal radiotherapy 
with an isocenter prescription.  CT scans for the radia-
tion treatment plan and irradiation were performed at 
2-10 mm intervals.  The gross tumor volume included 
the primary tumor and a clinically diagnosed metastatic 
lymph node.  The clinical target volume margin and 
planning target volume margin were both 5-10 mm.  
Non-metastatic subcarinal and ipsilateral hilar nodal 
stations were included in cases of elective nodal irradia-
tion [9 , 10].  The definitive radiation dose was delivered 
by a linear accelerator (Mevatron,  ONCOR,  or Primus;  
Canon Medical Systems,  Tochigi,  Japan).  The chemo-
therapy regimens consisted of cisplatin/docetaxel based 
on a prospective study of Okayama Lung Cancer Study 
Group Trial 0007 [1].  Durvalumab was not used 
because this drug was not launched in Japan within the 
survey period.
PET/CT protocol. All patients fasted for at least 6 
hours before the imaging assessments.  The PET/CT 
scans were acquired using a Biograph 16 PET/CT scan-
ner (Siemens Healthcare,  Erlangen,  Germany) at 
90 min after the intravenous administration of FDG 
(3.7 MBq/kg).  For photon attenuation correction and 
anatomical localization,  a low-dose CT scan was ini-
tially obtained from the level of the head to the mid-
thigh with a tube voltage of 120 kV,  an automatic tube 
current modulation using a reference tube current of 
50 mAs,  and a section thickness of 3 mm.  Subsequently,  
PET imaging was performed in three-dimensional 
mode for 3 min per bed position.  PET data were recon-
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structed using an ordered subsets expectation maximi-
zation algorithm and the following parameters: 5 itera-
tions,  4 subsets,  168 × 168 matrix,  and a section 
thickness of 3 mm.
PET/CT image analysis. Measurements of 
SUVmax,  metabolic tumor volume (MTV),  and total 
lesion glycolysis (TLG) were performed using special-
ized software (Syngo.  via Siemens Healthcare,  Erlangen,  
Germany).  The volume of interest (VOI) was manually 
drawn at the primary tumor and lymph node metastasis 
on PET/CT images,  and the software automatically 
delineated the contour of the target lesion (primary 
tumor and lymph node metastases) inside the VOI 
using an isocontour threshold method.  We set the 
absolute threshold for SUVmax at 2.5 to define the 
MTV based on a meta-analysis showing that fixed abso-
lute thresholds were suitable for evaluating the prog-
nostic value of MTV [4],  and the cutoff for the fixed 
value was an SUV of 2.5 [3].  The delineation of the 
target lesion was visually checked by a board-certified 
radiologist who did not have access to the patients’ 
prognoses.  The SUVmax,  MTV,  and TLG values of the 
delineated target lesion were automatically calculated.  
The MTV was defined as the metabolic volume of the 
target lesion with an SUV exceeding the defined thresh-
old of 2.5.  TLG values were calculated by multiplying 
the mean SUV of the target lesion by the MTV.
Statistical analysis. Survival curves were esti-
mated using the Kaplan-Meier method.  The medians of 
the volumetric PET parameters were used as the cutoff 
values.  Variables were grouped into 2 categories for 
statistical analyses,  and the medians were adopted as 
cutoff values for continuous variables.  The relation-
ships between the PET/CT parameters and the local 
control rate (LC),  DMFS rate,  PFS rate,  and OS rate 
were analyzed using the log-rank test for univariate 
analysis and the Cox proportional hazard model for 
multivariate analysis.  The comparison between the two 
groups was performed using Student’s t-test.  We calcu-
lated the mean follow-up interval of the CT,  magnetic 
resonance imaging,  and PET/CT examinations until the 
last day of follow-up for patients without recurrence 
and until the day of recurrence for patients with recur-
rence.  A p value < 0.05 (two-sided) was considered to be 
statistically significant.  R software,  version 3.5.1 (R 
Foundation for Statistical Computing) was used for all 
statistical analyses.
Results
The median follow-up period from the start of treat-
ment was 25.1 (range: 5.9-118.1) months.  Thirty 
patients met the eligibility criteria,  and Table 1 shows 
their characteristics.  The total dose of definitive radio-
therapy was 60 Gy/30 fractions in all patients.  Cisplatin/
docetaxel chemotherapy was used for all patients,  and 
cisplatin/vinorelbine was used as the second course in 
one patient because of a drug allergy.  For mediastinal 
tumors,  11 patients underwent endobronchial ultra-
sound-guided transbronchial needle aspiration biopsy,  
1 underwent endoscopic ultrasound-guided fine-needle 
aspiration biopsy,  1 underwent endobronchial ultra-
sound-guided transbronchial needle aspiration biopsy 
and open chest biopsy,  and 1 underwent a biopsy by 
mediastinoscopy.  For supraclavicular lymph nodes,  3 
patients underwent a biopsy.  Among recurrent patients,  
the longest time to recurrence was 40 months; there-
fore,  the examination intervals were measured up to 40 
months for patients without recurrence.  The average 
examination intervals in the high and low TLG groups 
were 10.98 weeks and 8.00 weeks (95% confidence 
interval of difference: −0.51 to +6.47),  respectively,  
and the difference was not significant (p = 0.09052).  The 
median SUVmax,  MTV,  and TLG were 16.04 (range:  
5.90-35.83),  78.82 cm3 (range: 15.09-547.00 cm3),  and 
588.07 (range: 47.09-4160.73),  respectively.  There were 
no significant differences in the average values of 
SUVmax,  MTV2.5,  or TLG2.5 between the adenocar-
cinoma and squamous cell carcinoma groups 
(p = 0.0656,  0.196 and 0.103,  respectively).
Table 2 shows the results of the univariate analysis of 
factors related to DMFS and PFS.  In the univariate 
analysis,  MTV and TLG were significant predictors of 
DMFS (p = 0.0003 and 0.0005,  respectively),  and 
SUVmax was not (p = 0.2).  MTV and TLG were signifi-
cant predictors of PFS (p = 0.001 and 0.0007,  respec-
tively),  and SUVmax was not (p = 0.08).  There were no 
significant factors in the multivariate analysis.
Figures 1 and 2 show the Kaplan-Meier curves of 
DMFS and PFS divided into 2 groups by the median 
values of the SUVmax,  MTV,  and TLG.  The three-year 
DMFS rate was 28.6% in patients with a low SUVmax 
and 47.6% in those with a high SUVmax,  13.3% in 
patients with a low MTV and 64.6% in those with a high 
MTV,  and 13.3% in patients with a low TLG and 65.2% 
in those with a high TLG (Fig. 1).  The three-year PFS 
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rate was 28.6% in patients with a low SUVmax and 
41.2% in those with a high SUVmax,  13.3% in patients 
with a low MTV and 57.8% in those with a high MTV,  
and 13.3% in patients with a low TLG and 57.8% in 
those with a high TLG (Fig. 2).
SUVmax,  MTV,  and TLG were not predictors for 
LC (p = 0.5,  0.5,  and 0.5,  respectively) (Fig. 3).  Lower 
age,  histology of adenocarcinoma,  and two cycles of 
concurrent chemotherapy were associated with a higher 
LC in the univariate analysis (p = 0.03,  0.03,  and 0.005,  
respectively).  There were no significant factors in the 
multivariate analysis.  SUVmax,  MTV,  and TLG were 
not predictors for OS (p = 0.7,  0. 5 and 0. 6,  respec-
tively) (Fig. 4).  The histology of the adenocarcinoma 
was associated with a higher OS on univariate analysis 
(p = 0.0008).  Elective nodal irradiation was performed 
in 7 patients and was not found to be correlated with LC 
(p = 0.5),  DMFS (p = 0.8),  PFS (p = 0.3),  or OS (p = 0.8).
Discussion
In this study,  we demonstrated that volumetric PET 
parameters were predictors of which patients had 
received definitive CCRT.
The outcome of chemoradiotherapy for stage III lung 
cancer has been shown to be significantly improved by 
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Table 1　 Patient characteristics
%
Age (years) Median (range) 64 (36-84) -
Sex Male 26 87
Female 4 13









Clinical stage IIIA 7 23
IIIB 23 77
Histology Adenocarcinoma 11 37
Squamous cell carcinoma 17 57
Non-small cell carcinoma 2 7
Lobea Upper 21 70
Lower 6 20
Lateralitya Right 17 57
Left 11 33
Smoking History Never 1 3
Former 15 50
Current 14 47
FEV1 (l)a Median (range) 2.17 (1.12-4.11) -
ECOG-PS 0 12 40
1 18 60
Cycles of concurrent chemotherapy 1 1 3
2 29 97
Cycles of adjuvant chemotherapy 0 28 93
1 2 7
SUVmax Median (range) 16.04 (5.90-35.83) -
MTV (cm3) Median (range) 78.82 (15.09-547.00) -
TLG Median (range) 588.07 (47.09-4160.73) -
ECOG-PS,  Eastern Cooperative Oncology Group performance status; FEV1,  forced expiratory volume in 1 sec; SUVmax,  maximum stan-
dardized uptake value; MTV,  metabolic tumor volume of SUVmax more than 2.5; TLG,  total lesion glycolysis of SUVmax more than 2.5.
aThese factors have missing values.
the use of durvalumab [11 , 12].  The improvement in 
PFS and OS could be attributed to the reduction of dis-
tant metastases.  However,  radiation pneumonitis is one 
of the serious adverse events of radiotherapy,  and the 
rate of grade 5 adverse events has been reported to be 
2.5% [13] and 4.4% [10].  In addition,  one of the major 
adverse events associated with immune checkpoint 
inhibitors is pneumonitis [14].  Thus,  these drugs can 
be used only after considering the balance between their 
benefits and the risk of pneumonitis; therefore,  predic-
tive biomarkers of distant metastases prior to CCRT are 
desirable,  as they can assist the attending physician in 
determining whether to administer durvalumab.
PET is a useful imaging technique for prediction in 
addition to diagnosis,  staging,  and radiotherapy plan-
ning in the case of malignancy [15 , 16].  Although 
SUVmax was initially adopted as a predictor for patients 
who received radiotherapy [2],  volumetric PET param-
eters have recently been adopted as prognostic factors.  
In our study,  SUVmax was not a predictor of LC,  
DMFS,  PFS,  or OS,  but the volumetric PET parame-
ters MTV and TLG were predictors of DMFS and PFS.  
Because SUVmax is a single-voxel value representing 
the most intense FDG uptake in the mass [4],  it does 
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Table 2　 Univariate analyses of factors associated with distant metastasis-free survival and progression-free survival
Factor DMFS PFS
event/total p-value event/total p-value
Age (years) <64 10/15 0.5 10/15 0.6
≥64 11/15 11/15
Sex Male 19/26 0.8 19/26 0.6
Female 2/4 2/4
T stagea 1-2 10/12 0.7 10/12 0.8
3-4 10/15 10/15
N stage 0-1 4/6 0.8 4/6 0.9
2-3 17/24 17/24
Clinical stage IIIA 4/7 0.5 4/7 0.9
IIIB 17/23 17/23
Histology Adenocarcinoma 8/11 0.05 8/11 0.2
others 13/19 13/19
Lobea Lower lobe 5/6 0.8 5/6 0.6
Upper lobe 15/21 15/21
Lateralitya Right 12/17 0.3 12/17 0.6
Left 8/10 8/10
Smoking history Never/Former 10/16 0.2 10/16 0.3
Current 11/14 11/14
FEV1 (l)a <2.2 11/15 0.8 11/15 0.9
≥2.2 10/13 10/13
ECOG-PS 0 8/12 0.7 8/12 0.9
1 14/18 13/18
Cycles of concurrent chemotherapy 1 1/1 0.7 1/1 0.4
2 20/29 20/29
Cycles of adjuvant chemotherapy 0 19/28 0.2 19/28 0.2
1 2/2 2/2
SUVmax <16 12/14 0.2 12/14 0.09
≥16 9/16 9/16
MTV (cm3) <79 14/15 0.0003 14/15 0.0005
≥79 7/15 7/15
TLG <590 14/15 0.001 14/15 0.0007
≥590 7/15 7/15
DMFS,  distant metastases free survival; ECOG-PS,  Eastern Cooperative Oncology Group performance status; FEV1,  forced expiratory 
volume in 1 sec; SUVmax,  maximum standardized uptake value; MTV,  metabolic tumor volume of SUVmax more than 2.5; PFS,  pro-
gression-free survival; TLG,  total lesion glycolysis of SUVmax more than 2.5.
aThese factors have missing values.
not always represent the volume or burden of the highly 
active lesions in malignant tumors.  In addition,  the 
tumor composition is heterogeneous,  and tumors are 
composed of non-active components such as necrotic 
tissue [17] or fibrotic scars,  which may cause inaccura-
cies in assessments based on SUVmax values.  SUVmax 
is also highly sensitive to image noise [18].  In contrast 
to SUVmax,  the MTV and TLG of volumetric PET rep-
resent both the three-dimensional tumor volume and 
metabolic activity.  In studies involving surgical resec-
tion for early stage disease [19],  CCRT for stage II-III 
disease [5 , 20],  preoperative CCRT followed by surgery 
for stage IIIA-N2 disease [21],  and chemotherapy for 
stage III-IV disease [7],  researchers concluded that vol-
umetric PET parameters are more useful as predictors 
than SUVmax.  Consistent with these reports,  volumet-
ric PET parameters were more useful than SUVmax as 
prognostic factors in our study.
In our study,  higher MTV and TLG resulted in 
higher DMFS and PFS rates,  which contradicted the 
results of a previous report [8].  To the best of our 
knowledge,  no papers have obtained the same results as 
our study.  The treatment options for stage III lung can-
cer are wide-ranging and include surgery,  preoperative 
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SUVmax low SUVmax high
3-y DMFS in high SUVmax; 47.6%
3-y DMFS in low SUVmax; 28.6%
Log-rank test p=0.2


















MTV low MTV high
3-y DMFS in high MTV; 64.6%
3-y DMFS in low MTV; 13.3%
Log-rank test p<0.001


















TLG low TLG high
3-y DMFS in high TLG; 65.2%
3-y DMFS in low TLG; 13.3%
Log-rank test p<0.001
Fig. 1　 Subgroup analysis of distant metastasis-free survival; (A) SUVmax; (B) MTV; (C) TLG.


















SUVmax low SUVmax high
3-y PFS in high SUVmax; 41.0%
3-y PFS in low SUVmax; 28.6%
Log-rank test p=0.09


















MTV low MTV high
3-y PFS in high MTV; 57.8%
3-y PFS in low MTV; 13.3%
Log-rank test p=0.001


















TLG low TLG high
3-y PFS in high TLG; 57.8%
3-y PFS in low TLG; 13.3%
Log－rank test p<0.001
Fig. 2　 Subgroup analysis of progression-free survival; (A) SUVmax; (B) MTV; (C) TLG.
radiotherapy followed by surgery,  chemoradiotherapy,  
and chemotherapy; therefore,  indications for definitive 
radiotherapy may vary greatly among institutions.  
While our study used standardized regimens of chemo-
therapy and radiation doses,  many previous reports 
have mixed different regimens and radiation doses [8],  
and this may have been responsible for the variation in 
results.  Other possible explanations for the discrepant 
results are described below.  PET accumulation is higher 
in poorly differentiated tumors [22].  Radiation therapy 
is highly effective for poorly differentiated tumors,  
which may explain the successful results in the high 
MTV and TLG groups.  Docetaxel leads to a G2-M-
phase cell cycle arrest of tumor cells and has a synergis-
tic effect with radiotherapy [23].  There may have been 
more tumor cells with higher activity and shorter dou-
bling times in the group with higher PET parameters,  
which may have resulted in a greater effect of CCRT in 
these patients.  Ganeshan et al.  found that the computed 
tomographic texture in NSCLC is associated with tumor 
hypoxia and angiogenesis [24].  Cook et al.  reported that 
prognosis can be predicted by texture analysis of 
intra-tumoral image heterogeneity with PET images of 
NCSLC patients who received chemoradiotherapy [25].  
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SUVmax low SUVmax high
3-y LC in high SUVmax; 52.1%
3-y LC in low SUVmax; 76.2%
Log-rank test p=0.5


















MTV low MTV high
3-y LC in high MTV; 62.9%
3-y LC in low MTV; 62.9%
Log-rank test p=0.5


















TLG low TLG high
3-y LC in high TLG; 62.9%
3-y LC in low TLG; 62.9%
Log-rank test p=0.5
Fig. 3　 Subgroup analysis of local control rate; (A) SUVmax; (B) MTV; (C) TLG.


















SUVmax low SUVmax high
3-y OS in high SUVmax; 57.4%
3-y OS in low SUVmax; 57.1%
Log-rank test p=0.7


















MTV low MTV high
3-y OS in high MTV; 63.8%
3-y OS in low MTV; 51.3%
Log-rank test p=0.5


















TLG low TLG high
3-y OS in high TLG; 64.2%
3-y OS in low TLG; 50.9%
Log-rank test p=0.6
Fig. 4　 Subgroup analysis of overall survival; (A) SUVmax; (B) MTV; (C) TLG.
Thus,  the volumetric PET value is not a simple expres-
sion of glucose metabolism and tumor burden and may 
indicate the influence of these more complicated factors.  
Data from additional studies and more research are 
warranted to validate these points.
Volumetric PET parameters were not prognostic 
factors for OS despite being prognostic factors for PFS.  
This difference in the predictive utility of PET for OS 
can be attributed to post-recurrence treatments such as 
molecular target drugs and immune checkpoint inhibi-
tors [26].  The pathology of adenocarcinoma was asso-
ciated with a high OS rate.  Pemetrexed is not recom-
mended because of its lower benefit in patients with 
squamous cell carcinoma compared to patients with 
adenocarcinoma [27],  while bevacizumab is not rec-
ommended because squamous cell carcinoma is a risk 
factor for serious adverse events [28].  It has been spec-
ulated that adenocarcinomatous pathology was a favor-
able prognostic factor in OS because of differences in 
drug indications and efficacy after recurrence.
We believe that the results of our study can help 
determine treatment strategies and the frequency of 
follow-up examinations after definitive CCRT.  The 
addition of durvalumab after definitive CCRT improves 
the prognosis and should be prescribed by physicians as 
much as possible.  Due to concerns regarding radiation 
pneumonitis,  cases with a V20 of 35% or more were 
excluded from the PACIFIC study [11 , 12],  and clinical 
use in such cases requires great caution.  Since the pro-
ton beam can produce a better dose distribution than 
the X-ray,  the V20 value can be reduced [29].  Thus,  the 
option of proton beam therapy may also be considered 
for patients with high V20 values who are likely to 
develop distant metastases as a result of volumetric PET 
parameters.  The prognosis is poor for those patients 
having both spinal metastases and rapidly progressing 
symptoms.  The 6-month survival rate for the good 
prognosis group with slower symptom progression is 
92.0%,  whereas that for the poor prognosis group with 
rapid symptom progression is 11.3% [30].  Therefore,  
early identification of distant metastases is as important 
as the treatment protocol.  It may be possible to improve 
a patient’s prognosis by assessing metastases at a short 
interval after CCRT in a group in which distant metas-
tasis is likely to occur based on volumetric PET param-
eters.
There are some limitations to our study.  First,  this 
study was a retrospective analysis with a small sample 
size,  which may be subject to unmeasurable bias.  
Second,  there may be selection bias because the attend-
ing physicians in the authors’ institutions tended to 
prioritize surgery after preoperative CCRT over defini-
tive CCRT in stage III NCSLC.  Third,  Cook et al.  
reported that PET texture analysis of intra-tumoral 
image heterogeneity can predict prognosis [25],  but we 
did not perform texture analysis.  Fourth,  since there 
were only 6 patients with a known pathological differ-
entiation grade,  we could not perform a statistical anal-
ysis of the effect of the degree of differentiation on the 
PET value.  Fifth,  the interval at which the examina-
tions were performed was not standardized,  which 
could have affected DMFS and PFS.  Despite these lim-
itations,  we showed that the group with high volumet-
ric PET parameters had a high DMFS rate.
In conclusion,  we demonstrated that volumetric 
PET parameters could serve as predictors in stage III 
NSCLC patients who received definitive CCRT with 
cisplatin/docetaxel.  Volumetric PET parameters may 
help physicians determine the best treatment modality 
and the most effective timing of follow-up examina-
tions.  Our findings are contrary to those of previous 
reports,  and further research is warranted to validate 
these results.
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